Form 4: C4 Therapeutics Chief Legal Officer, Jolie Siegel, Reports Stock Option Repricing

Jolie Siegel, Chief Legal Officer of C4 Therapeutics, reports the repricing of stock options on March 7, 2024.

Summary

• Jolie Siegel, the Chief Legal Officer of C4 Therapeutics, filed a Form 4 on March 8, 2024, reporting changes in beneficial ownership.
• The report details the repricing of several stock option grants on March 7, 2024.
• Specifically, two sets of options for 84,850 and 90,000 shares respectively, were repriced from $45.54 and $22.71 to $19.
• The repricing was approved by the Compensation Committee of the Issuer's Board of Directors.
• All other terms of the options, including the vesting schedules, remain unchanged.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The repricing could be seen as a positive for employee retention, but also potentially concerning if it reflects a significant decline in the stock price.

Positives

• The repricing of stock options may incentivize the officer to remain with the company.
• The repricing was approved by the Compensation Committee of the Board of Directors.

Industry Context

Stock option repricing is a common practice used by companies to retain and incentivize employees, especially when the stock price has declined significantly since the original grant date. This ensures that the options remain a valuable incentive for the employee.

Comparison to Industry Standards

• Stock option repricing is a fairly common practice, especially in the biotechnology industry, where stock prices can be volatile.
• Many companies, particularly smaller biotechs, use stock options extensively as part of their compensation packages.
• Comparing C4 Therapeutics' compensation practices to those of similar-sized biotech companies would provide a better understanding of whether this repricing is standard or unusual.

Stakeholder Impact

• Shareholders may view the repricing as a necessary measure to retain key personnel.
• Employees holding stock options will benefit from the lower exercise price.
• The repricing has no immediate impact on customers, suppliers, or creditors.

Key Dates